핵심요약

• AbbVie는 2025년에 12개의 제품이 연매출 10억 달러를 넘김
• 2026년 예상 순이익의 절반도 안 되는 배당금 지급 중
• 맥도널드는 100개국 이상에 45,000개 이상의 매장 운영
• 프랜차이즈 계약으로 안정적인 수익 창출
• 지속적인 배당 증가로 장기 투자 적합

도입

이 기사는 장기 보유용 배당주에 대한 심층 분석을 제공하며, 투자자에게 안정적인 수익을 추구하는 전략을 제시합니다. 특히, 영구적인 배당 성장과 기업의 경쟁력을 고려할 때, 이러한 주식은 포트폴리오의 핵심 자산으로 활용될 수 있다는 점이 중요합니다.

본문 1: 지속적인 배당 성장의 중요성

AbbVie의 12개의 제품이 2025년에 연매출 10억 달러를 넘긴 것은 기업의 다각화된 수익 기반을 보여줍니다. 이는 기업이 주요 특허 만료에도 불구하고 안정적인 성장을 유지할 수 있는 능력을 입증하며, 장기적으로 배당을 지속할 수 있는 기반이 됩니다. 이러한 안정성은 투자자에게 꾸준한 수익을 보장하며, 배당 재투자로 복리 효과를 기대할 수 있습니다.

본문 2: 글로벌 확장과 수익 모델의 안정성

맥도널드의 45,000개 이상의 매장과 100개국 이상에서의 운영은 글로벌 시장 점유율을 강조합니다. 프랜차이즈 계약으로 운영 비용을 분산시키고, 안정적인 수익을 창출하는 모델은 경제 상황의 변동성에 대한 저항력을 높입니다. 이는 장기적인 투자 관점에서 안정적인 현금 흐름을 기대할 수 있는 요인이 됩니다.

본문 3: 장기 투자 전망

AbbVie와 맥도널드의 경우, 지속적인 배당 성장과 안정적인 수익 모델은 장기 투자에 적합한 조건을 제공합니다. 그러나 경제 환경의 변화나 산업별 경쟁 압력은 항상 고려해야 할 리스크 요소입니다. 따라서 투자자는 이러한 기업의 재무 상태와 시장 동향을 지속적으로 모니터링하는 것이 중요합니다.

결론

이 기사는 지속적인 배당 성장과 안정적인 수익 모델을 갖춘 기업이 장기 투자에 적합하다는 점을 강조합니다. 특히, AbbVie와 맥도널드와 같은 기업은 글로벌 시장에서의 경쟁력과 안정적인 현금 흐름을 바탕으로 투자자에게 안정적인 수익을 제공할 가능성이 높습니다. 향후 경제 환경의 변화와 산업 동향을 주시하며, 이러한 기업의 장기적 전망을 평가하는 것이 중요합니다.

---

원문 링크: https://www.fool.com/investing/2026/06/22/5-dividend-stocks-to-buy-and-hold-forever/?.tsrc=rss

5 Dividend Stocks to Buy and Hold Forever

Buying a stock to hold forever isn't as simple as it sounds. Few companies can consistently win year in and year out, decade after decade. But it does happen in evergreen industries, such as healthcare and consumer goods, where brand power, deep pockets, and even patents can keep competitors at bay.

Achieving decades of uninterrupted dividend increases is a remarkable feat that only world-class companies can pull off. Remember, dividends are a cash expense, so a business must grow to continue sending all that money to shareholders.

These five blue chip dividend stocks have done it. No, they won't make you rich overnight. But don't underestimate the compounding effect of reinvesting a growing dividend. They are still worth buying and carving out permanent spots in your portfolio for.

Image source: The Motley Fool.

Biopharmaceutical giant AbbVie ( ABBV 2.14% ) has a storied history, dating back decades to its time as part of Abbott Laboratories , before it began trading independently in 2013. Counting the Abbott years, AbbVie is a Dividend King , a company with at least 50 consecutive annual dividend increases. Today, AbbVie develops treatments across immunology, oncology, neuroscience, eye care, and aesthetics, and has 12 products that topped $1 billion in sales in 2025.

AbbVie's diverse sales base is ideal for a buy-and-hold stock, and the company has proven it can adapt as key patents, such as Humira, expired in 2023. AbbVie's dividend is still less than half of its 2026 earnings estimates, and Wall Street anticipates annualized earnings growth above 20% over the next several years.

Fast-food pioneer McDonald's ( MCD 1.84% ) is a global burger empire today with more than 45,000 locations across over 100 countries. Its food appeals to value-focused consumers and is a symbol of Americana worldwide.

The company franchises its restaurants to operators who shoulder most of the operating expenses. The fees and royalties from all those stores generate steady, recurring revenue.

As a result, McDonald's has been a fantastic dividend stock for a long time. The company is essentially knocking on the door of Dividend King status, poised to join that exclusive club with its next dividend raise later this year. McDonald's continues to expand and innovate its way to growth .

The dividend is only 57% of 2026 earnings estimates, and analysts see McDonald's extending its streak, with high-single-digit earnings growth expected ahead.

Few names resonate as Johnson & Johnson ( JNJ 2.48% ) does in the healthcare space. The company is a stalwart in pharmaceuticals and medical devices after spinning off its consumer products business as Kenvue .

Johnson & Johnson is also a legendary dividend stock with a whopping 64 consecutive dividend increases, one of the longest streaks on record. The healthcare behemoth has a diverse business, anchored by an AAA-rated corporate balance sheet.

Johnson & Johnson is a textbook widow-and-orphan stock -- a boring, slow-growing dividend payer investors can depend on. It's only natural to have it on this list. Johnson & Johnson's dividend is also still in excellent financial health, consuming under half of its estimated 2026 earnings, even after all these increases. Analysts anticipate the business grinding forward, with annual earnings growth averaging 8% to 9% over the coming years.

Almost every American shops at Walmart ( WMT 0.80% ) . Its massive scale enables it to procure and sell goods at the lowest prices, creating a self-fulfilling loop that makes Walmart tougher to compete with. The company isn't recession-proof, but so many people buy their groceries and household staples there that it has maintained and increased its dividend for 53 years and counting.

When e-commerce disrupted the retail industry, Walmart utilized its stores and supply chain to compete with Amazon . E-commerce is now a genuine growth engine for Walmart. Analysts see the company growing earnings by an average of 9% over the next three to five years, which should help it continue growing its bottom line and dividend. The dividend is only 34% of Walmart's 2026 earnings estimates, so there's plenty of cushion.

Global medical technology company Becton, Dickinson ( BDX +1.67% ) sells healthcare products and systems across its four business segments: medical essentials, connected care, biopharma systems, and interventional. With over 33,000 patents and $1 billion in annual research and development spending, Becton, Dickinson has been at the cutting edge of healthcare for decades. And the stock is a Dividend King, with 54 consecutive yearly dividend increases.

Analysts currently estimate the company's earnings will grow by just over 1% annually over the next several years. That's OK. You're not going to find a buy-and-hold stock that's firing on all cylinders all the time. Plus, the dividend is still only one-third of 2026 earnings estimates, so investors can feel confident in the dividend's safety while waiting for management to reignite growth.

Source: https://www.fool.com/investing/2026/06/22/5-dividend-stocks-to-buy-and-hold-forever/?.tsrc=rss